@article{ea631d4cca854d1da7a52937083a4cdc,
title = "Digital therapeutics for mental health: Is attrition the Achilles heel?",
keywords = "ADHD, Alzheimer's disease, PTSD, addiction, anxiety, autism, depression, schizophrenia",
author = "Adaora Nwosu and Samantha Boardman and Husain, {Mustafa M.} and Doraiswamy, {P. Murali}",
note = "Funding Information: MH has received grants from NIMH, NIA, Brain Initiative and Stanley Foundation for other projects. For other projects, PMD has received grants from NIA, DARPA, DOD, ONR, Salix, Avanir, Avid, Cure Alzheimer's Fund, Karen L. Wrenn Trust, Steve Aoki Foundation, and advisory fees from Apollo, Brain Forum, Clearview, Lumos, Neuroglee, Otsuka, Verily, Vitakey, Sermo, Lilly, Nutricia, and Transposon. PD is a co-inventor on patents for diagnosis or treatment of neuropsychiatric conditions and owns shares in biotechnology companies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. ",
year = "2022",
month = aug,
day = "5",
doi = "10.3389/fpsyt.2022.900615",
language = "English (US)",
volume = "13",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Research Foundation",
}